Evidence map›Paper›PMID 34080093›Full record

ReviewBreast cancer research and treatment2021

Undercutting efforts of precision medicine: roadblocks to minority representation in breast cancer clinical trials.

Geetanjali Saini, Keerthi Gogineni, Rick A Kittles, Ritu Aneja

Abstract readReview
PubMed Publisher
In one paragraph

Review in Breast cancer research and treatment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Geetanjali SainiDepartment of Biology, Georgia State University, 100 Piedmont Ave, Atlanta, GA, 30303, USA.
Keerthi GogineniDepartment of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, 30322, USA.
Rick A KittlesDivision of Health Equities, Department of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, CA, 91010, USA.
Ritu AnejaDepartment of Biology, Georgia State University, 100 Piedmont Ave, Atlanta, GA, 30303, USA. raneja@gsu.edu.ORCID http://orcid.org/0000-0003-4489-5320

Funding

HSET as a racial disparity biomarker for TNBC patientsR01CA239120 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ANEJA, RITU · 2019 to 2024
$3.0M
National Cancer Institutes of Health R01CA239120NCI NIH HHS R01 CA239120
6 · The paper itself

Abstract

Precision (or personalized) medicine holds great promise in the treatment of breast cancer. The success of personalized medicine is contingent upon inclusivity and representation for minority groups in clinical trials. In this article, we focus on the roadblocks for the African American demographic, including the barriers to access and enrollment in breast oncology trials, the prevailing classification of race and ethnicity, and the need to refine monolithic categorization by employing genetic ancestry mapping tools for a more accurate determination of race or ethnicity.

Indexed as

Breast NeoplasmsPrecision MedicineBlack or African AmericanClinical Trials as TopicFemaleHispanic or LatinoHumansMinority GroupsAfrican AmericansAncestry informative markersOncology trialsRace/ethnicity classification

Identifiers

PMID34080093

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.